Your GP just proposed a continuation fund. The pitch deck shows a familiar asset, a fresh thesis, and a request for you to roll your capital into another five-year hold. The question you face is not whether continuation vehicles are legitimate (they are) or whether the market is growing (it is). The question is whether this specific transaction aligns your interests with the GP’s, and whether the value-creation runway genuinely justifies extending the hold rather than exiting now.
For LPs in SME-focused funds, this decision carries real weight. You committed capital expecting a defined fund life. Now that timeline is shifting, and you need a framework for evaluating whether the GP’s conviction is well-founded or whether you are being asked to subsidize a parked asset that failed to find a buyer.
This article provides that framework. Not a legal explainer or a market overview, but an alignment-and-value-creation lens for reading GP-led continuation vehicles. I will walk through the signals that separate quality deals from problematic ones, the conflicts you must test, and what portfolio CEOs should expect operationally when their company moves into a continuation vehicle structure.
What a continuation fund actually represents in practice
A continuation fund (also called a continuation vehicle or CV) is a GP-led secondaries transaction where a sponsor transfers one or more assets from an existing fund into a new vehicle. Existing LPs can either roll their investment into the new structure or sell to incoming secondary buyers at a negotiated price.
The mechanics matter less than the underlying question: why is the GP choosing this path instead of a traditional exit? Every continuation vehicle private equity transaction represents a thesis that the asset has more value to create under continued GP ownership than it would realize through a sale to a strategic buyer, another sponsor, or a public market.
According to Evercore, GP-led secondaries volume reached $52 billion in 2023, representing roughly 48% of total secondary market activity. This is not a niche transaction type. It has become a mainstream tool in private equity exit strategies, which makes evaluating these deals a core competency for any LP or portfolio company executive.
When a longer hold reflects conviction versus a lack of exit options
The first question to ask is whether the continuation fund reflects genuine conviction or necessity. These are different situations that demand different responses.
Conviction-Driven Continuation
A conviction-driven continuation vehicle typically emerges when the GP believes the asset has entered a phase of accelerating value creation that a new owner would capture. Common scenarios include:
- A platform company that has completed its add-on acquisition strategy and is now positioned for organic growth at scale
- A business that has invested heavily in product development or market expansion, with payoff expected in the next 24-36 months
- A company benefiting from a sector tailwind that is still in early innings
In these cases, the GP is essentially saying: “We built something valuable, the value-creation runway extends beyond our fund life, and we want to capture more of the upside we created.”
Necessity-Driven Continuation
A necessity-driven continuation vehicle emerges when the GP cannot find an acceptable exit. Warning signs include:
- A failed sale process with no credible bids at acceptable valuations
- Fund life expiration forcing a transaction regardless of readiness
- An asset that has underperformed and needs more time to reach baseline expectations, not upside
The difference matters because necessity-driven CVs often set unrealistic pricing, underestimate the operational work required, and misalign incentives between GPs and LPs. According to Cambridge Associates, single-asset continuation fund transactions with clear strategic rationales outperform those driven primarily by fund-life constraints by a meaningful margin.
Rollover, crystallized carry, and the conflicts you must test
Alignment in a continuation vehicle is not assumed. It must be tested through specific structural features.
GP Rollover
The GP’s rollover percentage into the new vehicle is the most direct signal of conviction. A GP that rolls 100% of its crystallized carry and commits meaningful new capital is demonstrating skin in the game. A GP that takes substantial carry off the table while asking LPs to recommit is creating a misalignment.
Industry practice varies, but Jefferies reports that median GP rollover in recent continuation fund transactions sits between 50-70% of crystallized carry. You should understand not just the percentage but the absolute dollar amount relative to the GP’s economics.
Crystallized Carry
Continuation vehicles allow GPs to crystallize carried interest at the transaction price. This creates an inherent conflict: the GP has an incentive to maximize the valuation at which the CV closes, regardless of whether that valuation is realistic for future returns.
Questions to ask:
- What carry is being crystallized at this transaction?
- How does the crystallized carry compare to what the GP would have earned in a straight sale?
- Is the GP taking liquidity while asking LPs to defer theirs?
New Fund Economics
The continuation vehicle will have its own fee structure, typically including management fees and carried interest. You need to evaluate whether these economics are reasonable given the asset’s expected hold period and return profile. A CV that charges full management fees on a mature asset with limited operational needs is extracting value from LPs.
Understanding these dynamics is essential for anyone monitoring private equity market intelligence and making informed decisions about continuation fund participation.
The value-creation runway a continuation vehicle must justify
Every continuation vehicle implicitly makes a claim about future value creation. That claim must be specific, credible, and large enough to justify the illiquidity premium LPs are accepting by rolling into a new multi-year hold.
The Math Test
If the CV is priced at a 2.0x multiple on original cost and the GP is projecting a 3.0x exit, LPs rolling in are underwriting a 1.5x return over the new hold period. After fees and carry, the net multiple to LPs might be 1.3x. Is that attractive given the risk and illiquidity? The answer depends on your alternatives and your view of execution risk.
The Specificity Test
A credible private equity value creation thesis for a CV should be concrete:
- What specific initiatives will drive EBITDA growth?
- What margin expansion is expected, and from which operational changes?
- What multiple expansion is assumed, and what drives it?
- What capital expenditures or investments are required?
A CV pitch that relies primarily on multiple expansion without clear operational drivers is a yellow flag. The private equity market is not reliably pricing assets higher just because GPs hold them longer.
The Runway Test
Value creation has diminishing returns over time. A company that has been under PE ownership for five years has typically harvested the low-hanging fruit. The value creation plan for a continuation vehicle needs to identify genuine second-order opportunities, not recycled versions of the original thesis.
According to Bain’s 2024 Global Private Equity Report, the median hold period for PE-backed companies has extended to approximately 5.9 years, making continuation vehicles more common but also raising the bar for what incremental value creation looks like in year six, seven, or eight of ownership.
Pricing, fairness process, and LP optionality
The pricing of a continuation fund determines whether rolling LPs are buying in at fair value or subsidizing the GP’s exit. The fairness process is supposed to protect LPs, but it has limitations.
How CV Pricing Works
Continuation vehicles are typically priced through a competitive process where secondary buyers bid on the right to provide liquidity to selling LPs. The winning bid sets the transaction price. Rolling LPs are implicitly buying in at this price.
The issue is that secondary buyers are sophisticated and price accordingly. They are not paying strategic premiums. A CV priced at 12x EBITDA when strategics might pay 14x means rolling LPs are entering at the secondary market’s assessment of value, not at what a full sale process might achieve.
The Fairness Opinion
Most CV transactions include a fairness opinion from an independent financial advisor. This opinion attests that the price is within a reasonable range. However, fairness opinions have wide ranges, and “fair” is not the same as “optimal for LPs.”
Questions to ask:
- What was the range in the fairness opinion?
- Where does the transaction price fall within that range?
- Was a full sale process run before the CV was selected?
- Why did the GP choose a CV over a sale at the current valuation?
LP Optionality
Rolling versus selling is the core decision for existing LPs. Key considerations:
- Liquidity needs: If you need distributions, selling may be appropriate even if you believe in the thesis
- Portfolio concentration: Rolling increases concentration in a single asset
- GP conviction: If you trust the GP’s judgment and alignment, rolling captures upside
- Alternative deployment: What would you do with the proceeds if you sold?
Understanding this decision framework is part of a broader literacy around private equity secondaries and how they function in portfolio management.
Signals that separate quality continuation vehicles from parked assets
Not all continuation funds are created equal. Here are the signals that distinguish genuinely attractive CVs from transactions that primarily serve GP interests.
Positive Signals
- High GP rollover: 80%+ rollover of crystallized carry suggests alignment
- Fresh GP capital: New GP commitment beyond rollover demonstrates conviction
- Clear operational thesis: Specific initiatives with defined milestones and accountability
- Strong underlying performance: Asset is exceeding plan, not catching up to it
- Competitive secondary process: Multiple bidders at attractive prices
- Shorter projected hold: 2-3 year thesis is more credible than 5+ years
- Defined exit path: GP can articulate who the likely buyer is and why they would pay more later
Negative Signals
- Low GP rollover: GP taking significant carry off the table
- Failed sale process: CV emerged after no acceptable bids
- Vague thesis: “Continue executing the plan” without specifics
- Underperforming asset: CV is a turnaround bet, not a growth bet
- Single bidder: Limited price discovery
- Extended hold period: Five more years on an already-mature asset
- Heavy fee load: Full management fees on a concentrated, mature position
Continuation vehicles that destroy alignment and returns
Let me illustrate how CVs can go wrong. Consider an illustrative scenario (not a specific deal):
A GP has held a healthcare services platform for six years. The original fund is approaching its contractual end. A sale process generated bids at 8-9x EBITDA, below the GP’s expectations of 11-12x. Instead of accepting the market’s verdict, the GP proposes a continuation vehicle priced at 10x, arguing that a few more years of growth will justify the premium.
The problems multiply:
- The GP crystallizes carry at 10x, taking liquidity despite LPs not receiving their expected exit
- GP rollover is 40%, meaning the GP is de-risking while asking LPs to maintain exposure
- The value-creation thesis is essentially “revenue will grow 8% annually,” which was the original thesis and has not changed
- The secondary buyer pool is thin because sophisticated buyers recognize the 10x price is above fair value
- LPs who sell receive 10x, but the next exit will likely also be at 10x or lower given the asset’s maturity
In this scenario, the CV primarily served to extend GP fee income and crystallize carry at an inflated price. LPs who rolled captured minimal upside while bearing continued execution risk.
According to PitchBook data, a meaningful minority of GP-led secondaries transactions have delivered returns below the pricing multiple at which rolling LPs entered. This is not theoretical risk.
What a portfolio CEO should expect operationally under a continuation vehicle
If you are running a company that is moving into a continuation vehicle, your operational reality is about to change. Here is what to expect.
Renewed Scrutiny
The CV process involves significant due diligence, often rivaling a sale process. Secondary buyers and rolling LPs will scrutinize your financials, operations, and growth plans. Expect management presentations, data room requests, and questions about every assumption in your forecast.
A Fresh Value-Creation Plan
The GP will likely present a new or refreshed operator’s value-creation plan to justify the CV. You may be asked to commit to initiatives you did not originate. Make sure you understand what is being promised on your behalf and whether the resources will be available to deliver.
Potential Board Changes
New secondary buyers may request board representation. Your board composition could shift, introducing new voices with different priorities and timelines.
Ongoing LP Communication
CV structures often involve more granular LP reporting than traditional fund structures. Be prepared for increased transparency requirements and more frequent updates.
Management Incentives
Your equity compensation will likely be restructured as part of the CV. Negotiate carefully. The new strike price, vesting schedule, and exit scenarios matter for your personal economics. Do not assume the GP will automatically protect your interests in the restructuring.
Extended Timeline
You signed up for PE ownership with an expected exit in 4-6 years. Now that timeline is extending. Consider whether you want to run this company for another 3-5 years under PE ownership. If not, this is the moment to have that conversation.
The continuation-vehicle conviction scorecard
Use this scorecard to evaluate any continuation fund proposal. Score each dimension from 1 (poor) to 5 (excellent) and sum for a total assessment.
| Dimension | What to Evaluate | Score 1-5 | Notes |
|---|---|---|---|
| GP Rollover | Percentage of crystallized carry rolled into CV; additional new GP commitment | 5 = 80%+ rollover plus new capital; 1 = <30% rollover, no new capital | |
| Carry Crystallization | Amount of carry crystallized vs. rolled; GP liquidity vs. LP liquidity | 5 = Minimal crystallization, aligned liquidity; 1 = GP taking large payout while LPs defer | |
| Value-Creation Specificity | Named initiatives with milestones, accountability, and defined ROI | 5 = Detailed operational plan with clear drivers; 1 = Generic “continue growth” thesis | |
| Value-Creation Magnitude | Expected return to rolling LPs after fees and carry; attractiveness vs. alternatives | 5 = Net 2.0x+ expected over 3 years; 1 = Net 1.2x or below over extended period | |
| Asset Performance | Current performance vs. original underwriting; trajectory | 5 = Exceeding plan; 1 = Significantly behind plan | |
| Pricing Process | Competitive bid process; fairness opinion range; comparison to potential strategic sale | 5 = Multiple bidders, price at top of range, no failed sale; 1 = Single bidder, bottom of range, post-failed process | |
| LP Optionality | Ability to sell at fair price; liquidity mechanics; reinvestment alternatives | 5 = Full liquidity option at attractive price; 1 = Forced roll or unfavorable sale terms | |
| Hold Period | Projected additional hold and its credibility; defined exit path | 5 = 2-3 years with clear buyer thesis; 1 = 5+ years with vague exit | |
| Fee Structure | Management fees and carry appropriate for asset maturity and expected activity | 5 = Reduced fees reflecting mature asset; 1 = Full fees on concentrated, low-touch position | |
| GP Track Record | GP’s history with CVs and extended holds; realized returns on prior CVs | 5 = Proven CV execution with strong returns; 1 = No CV history or poor prior outcomes |
Scoring Interpretation:
- 40-50: Strong alignment and value-creation case. Rolling is likely attractive.
- 30-39: Mixed signals. Proceed with caution, negotiate terms, or consider partial roll.
- 20-29: Significant concerns. Default to selling unless specific issues can be addressed.
- Below 20: Material misalignment. Selling is likely the appropriate response.
Questions to ask before rolling
Before making a roll-or-sell decision on any GP-led secondaries transaction, work through these questions:
On Alignment
- What percentage of crystallized carry is the GP rolling?
- Is the GP committing fresh capital beyond rollover?
- How much liquidity is the GP taking relative to LPs?
- How do the new fund economics compare to the original fund?
On Value Creation
- What specific initiatives will drive EBITDA growth?
- What is the margin expansion target and how will it be achieved?
- What multiple expansion is assumed, and what justifies it?
- What capital investment is required and what is the expected ROI?
- Why couldn’t these initiatives be completed under the original fund?
On Pricing
- How many secondary buyers participated in the process?
- Where does the transaction price fall within the fairness opinion range?
- Was a full sale process run? If so, why was it rejected?
- How does the CV price compare to what strategics might pay?
On Exit
- Who is the expected buyer in 2-3 years?
- Why will they pay more then than buyers would pay now?
- What happens if the thesis does not materialize?
A decision framework, not a default position
Continuation funds are neither inherently good nor inherently problematic. They are tools that can serve LP interests when properly structured and executed, or extract value from LPs when misaligned.
The framework for evaluation is straightforward:
- Test the thesis: Is longer ownership conviction-driven or necessity-driven?
- Test alignment: Does the GP’s rollover and fee structure demonstrate skin in the game?
- Test value creation: Is the runway specific, credible, and large enough to justify illiquidity?
- Test pricing: Is the process competitive and the price fair relative to alternatives?
- Test optionality: Can you sell at a reasonable price if you prefer liquidity?
Use the Conviction Scorecard as a structured tool for working through these questions. A strong CV should score well across all dimensions. Weakness in any dimension is a signal for caution, not necessarily rejection, but careful negotiation and clear-eyed assessment of risk.
For portfolio company CEOs, the message is simpler: understand what is being promised on your behalf, negotiate your incentives carefully, and be honest with yourself about whether you want to run this company for another extended PE hold.
Subscribe to the Growth Shuttle research briefing for the continuation-vehicle research briefing, and download the Continuation-Vehicle Conviction Scorecard.